The global targeted DNA RNA sequencing market size was valued at USD 10.85 billion in 2023 and is anticipated to reach around USD 64.43 billion by 2033, growing at a CAGR of 19.5% from 2024 to 2033.
DNA and RNA sequencing enables the precise sequence of nucleotides in DNA or RNA molecules, which is critical to understanding genetic information and biological functions the target DNA/RNA structure focuses on specific genes or regions, increasing the accuracy of diagnosis and personalized treatment.
With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to find the pathogenic variation at a comparatively earlier point in the process, which diagnoses and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.
The market development can be attributed to the introduction of Next Generation (NGS) technology. This method improves quantification by providing read counts of specific molecular identifiers bound to DNA molecules before amplification, rather than counting all reads. In addition, genetic testing has increased the data set, allowing researchers, clinicians, and patients to better understand genetic susceptibility to specific diseases. The market for DNA/RNA sequencing is growing due to technological advances, cost reductions, and increasing demand for personalization and precision medicine in oncology and rare diseases.
Report Attribute | Details |
Market Size in 2024 | USD 12.97 Billion |
Market Size by 2033 | USD 64.43 Billion |
Growth Rate From 2024 to 2033 | CAGR of 19.5% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Product, workflow, application, type, end use, region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Key Companies Profiled | Illumina; F. Hoffman-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Oxford Nanopore Technologies; PierianDx; Genomatix GmbH; DNASTAR, Inc.; Perkin Elmer, Inc. |
The next generation sequencing (NGS) segment dominated the market in 2023 pertaining to the offering of NGS technology with several advantages over older methods, including the ability to sequence a much larger number of targets simultaneously and at a significantly lower cost. These factors highlight the significance of NGS, which is the most widely used workflow in targeted sequencing by all researchers and healthcare service providers in the market.
The others segment is projected to grow at a substantial rate over the forecast period. This segment extends to other fields apart from drug discovery, human health, and plant & animals as highlighted below. The emergence of research branches such as pharmacogenomics deals with the impact of genes on the effectiveness of drugs, and metagenomics, which is focused on determining the genomes of microbes in an environment. This has unveiled new opportunities for targeted sequencing in tools, thus stimulating segment growth.
The sequencing segment dominated the market in 2023. The dominance majorly highlights its role in every stage of the process. The sequencing segment defines the particular order of nucleotides in the targeted DNA or RNA, which creates the basis for all other analyses contributing to the market growth.
The pre-sequencing segment is projected to grow at a substantial rate over the forecast period. This is due to pre-sequencing aspects, for instance, library preparation and target enrichment is more efficient and specific in isolating the required areas. Secondly, due to the increasing need for high-throughput sequencing, there is a higher requirement for the pre-sequencing processes for large samples.
Drug discovery dominated the market and accounted for a share of 42.75% in 2023. This is attributed to the pharmaceutical companies that target sequencing to determine genetic factors that are related to specific diseases. Additionally, it accelerates drug development by concentrating on targets and guarantees the formation of more efficient medicines with fewer side effects. With the increasing focus on personalized medicine, targeted sequencing has become an invaluable tool for drug development tailored to individual patient needs, further propelling its growth.
Plant and animal sciences are expected to register a CAGR of 19.9% during the forecast period. This is due to the agriculture sector which makes it possible to determine genes associated with the desired characteristics in plants and animals. Additionally, in animal breeding, targeted sequencing assists in selecting animals with superior traits leading to improved livestock quality and productivity. Veterinary medicine is widely applied in targeted sequencing to identify diseases that affect animals and formulate individual treatment plans.
The DNA based targeted sequencing segment dominated the market in 2023. This is due to DNA analysis offering a more stable target compared to RNA, which degrades faster. This stability allows convenience in sample handling, storage, and analysis. Targeted DNA sequencing is enhanced by its precise drug compatibility. By targeting specific genes associated with diseases, researchers can develop personalized therapies. Furthermore, DNA sequencing is a more advanced technology than RNA, providing a faster and more cost-effective workflow.
The RNA based targeted sequencing segment is projected to grow at a substantial rate over the forecast period. The newer methods aimed at stabilizing RNA are helping to overcome the basic problem of RNA instability, making RNA less risky to target. Additionally, RNA sequencing provides a dynamic view of gene expressional analysis in the cellular processes and mechanisms in the development of diseases drives market growth.
The academic research segment dominated in 2023 due to its vital role in driving scientific discoveries. Using custom research, researchers can identify specific genes or regions for in-depth analysis, allowing them to explore specific research questions in more detail. Additionally, targeted sequencing offers a powerful tool for uncovering new disease mechanisms. By efficiently identifying genetic variants, researchers can gain important insights into how diseases develop and progress, paving the way for future breakthroughs.
The pharma and biotech entities segment is projected to grow at a CAGR of 20.2% over the forecast period. They are more effective because targeted sequencing helps to identify each key component specifically related to diseases. Secondly, it shortens drug development timelines as researchers avoid irrelevant pathways, hence allowing patients to access new drugs in the shortest time possible.
North America targeted the DNA RNA sequencing market and accounted for largest revenue share of 42.11% in 2023 owing to the region being home to many well-resourced research organizations and implementing pharma organizations, which have expressed a very high interest in using this technology to aid drug discovery and development. Additionally, North America has the appropriate legal framework and high disposable incomes, and targets sequencing for a broad application in diagnosis and personal approaches in the healthcare field.
U.S. Targeted DNA RNA Sequencing Market Trends
The U.S. targeted DNA RNA sequencing market dominated North America with a share of 87.3% in 2023 due to a significant rise in government funding for research and policies, besides a rich pool of the biotech and pharma industry and research universities. Furthermore, investment and expertise enhance the advancement and utilization of the targeted sequencing across different areas.
Europe Targeted DNA RNA Sequencing Market Trends
Europe targeted DNA RNA sequencing market was identified as a lucrative region in 2023. This growth is fueled by governmental support for genomics research and more attention paid to personalized medicine programs. Based on these factors the market players and researchers have a conducive environment to increase the use of targeted sequencing technologies in Europe.
UK targeted DNA RNA sequencing market is expected to grow rapidly in the coming years due to a solid academic foundation of genomics in the UK, and some research facilities are already applying genomics in medical research. Secondly, government-related schemes such as the 100,000 Genomes Project and the infrastructure in genomics are promoting the adoption of targeted sequencing in the UK healthcare system.
Asia Pacific Targeted DNA RNA Sequencing Market Trends
Asia Pacific targeted DNA RNA sequencing market is anticipated to witness significant growth. This surge is driven by the increase in disposable income and rising government expenditure in genomics. These factors have created more demand in the healthcare sector and unlocked new opportunities for sequencing technologies for diagnostics and personalized medicine in the regional market.
China targeted DNA RNA sequencing market held a substantial market share in 2023 due to a steady rise in the population to advance a massive demand for superior medical services. Additionally, the government policies drive the local industries to develop and increase access to targeted sequencing systems for research and diagnostics.
The following are the leading companies in the targeted DNA RNA sequencing market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Targeted DNA RNA Sequencing market.
By Product
By Workflow
By Application
By Type
By End Use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Targeted DNA RNA Sequencing Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Targeted DNA RNA Sequencing Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Targeted DNA RNA Sequencing Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Targeted DNA RNA Sequencing Market: Technology Movement Analysis, 2024 & 2033(USD Million)
4.3. NGS
4.3.1. NGS Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.2. Method Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.2.1. Exome Sequencing
4.3.2.1.1. Exome Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.2.2. Enrichment Sequencing
4.3.2.2.1. Enrichment Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.2.3. Amplicon Sequencing
4.3.2.3.1. Amplicon Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.2.4. Others
4.3.2.4.1. Others Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3. Application Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3.1. Cancer Gene Sequencing
4.3.3.2. Cancer Gene Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3.3. Inherited Disease Screening
4.3.3.4. Inherited Disease Screening Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3.5. Drug Development
4.3.3.6. Drug Development Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3.7. Forensic Genomics
4.3.3.8. Forensic Genomics Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.3.3.9. 16S Ribosomal RNA (rRNA)
4.3.3.10. 16S Ribosomal RNA (rRNA) Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
4.4. Others
4.4.1. Others Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 5. Targeted DNA RNA Sequencing Market: Workflow Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Targeted DNA RNA Sequencing Market: Workflow Movement Analysis, 2024 & 2033(USD Million)
5.3. Pre-sequencing
5.3.1. Pre-sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
5.4. Sequencing
5.4.1. Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
5.5. Data Analysis
5.5.1. Data Analysis Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 6. Targeted DNA RNA Sequencing Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Targeted DNA RNA Sequencing Market: Application Movement Analysis, 2024 & 2033(USD Million)
6.3. Human Biomedical Research
6.3.1. Human Biomedical Research Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
6.4. Plant & Animal Sciences
6.4.1. Plant & Animal Sciences Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
6.5. Drug Discovery
6.5.1. Drug Discovery Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
6.6. Others
6.6.1. Others Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 7. Targeted DNA RNA Sequencing Market: Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Targeted DNA RNA Sequencing Market: Type Movement Analysis, 2024 & 2033(USD Million)
7.3. DNA Based Targeted Sequencing
7.3.1. DNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
7.4. RNA Based Targeted Sequencing
7.4.1. RNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 8. Targeted DNA RNA Sequencing Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Targeted DNA RNA Sequencing Market: End Use Movement Analysis, 2024 & 2033(USD Million)
8.3. Academic Research
8.3.1. Academic Research Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
8.4. Hospitals & Clinics
8.4.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
8.5. Pharma & Biotech Entities
8.5.1. Pharma & Biotech Entities Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
8.6. Others
8.6.1. Others Market Revenue Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 9. Targeted DNA RNA Sequencing Market: Regional Estimates & Trend Analysis
9.1. Targeted DNA RNA Sequencing Market Share, By Region, 2024 & 2033(USD Million)
9.2. North America
9.2.1. North America Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.2.2. U.S.
9.2.2.1. U.S. Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.2.3. Canada
9.2.3.1. Canada Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.2.4. Mexico
9.2.4.1. Mexico Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3. Europe
9.3.1. Europe Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.2. UK
9.3.2.1. UK Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.3. Germany
9.3.3.1. Germany Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.4. France
9.3.4.1. France Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.5. Italy
9.3.5.1. Italy Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.6. Spain
9.3.6.1. Spain Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.7. Denmark
9.3.7.1. Denmark Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.8. Sweden
9.3.8.1. Sweden Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.3.9. Norway
9.3.9.1. Norway Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.2. China
9.4.2.1. China Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.3. Japan
9.4.3.1. Japan Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.4. India
9.4.4.1. India Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.5. South Korea
9.4.5.1. South Korea Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.6. Australia
9.4.6.1. Australia Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.4.7. Thailand
9.4.7.1. Thailand Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.5. Latin America
9.5.1. Latin America Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.5.2. Brazil
9.5.2.1. Brazil Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.5.3. Argentina
9.5.3.1. Argentina Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.6. Middle East and Africa
9.6.1. Middle East and Africa Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.6.2. Saudi Arabia
9.6.2.1. Saudi Arabia Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.6.3. UAE
9.6.3.1. UAE Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.6.4. South Africa
9.6.4.1. South Africa Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
9.6.5. Kuwait
9.6.5.1. Kuwait Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 & 2033(USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Company Heat Map Analysis
10.4. Company Profiles
10.4.1. Illumina
10.4.1.1. Participant’s Overview
10.4.1.2. Financial Performance
10.4.1.3. Product Benchmarking
10.4.1.4. Recent Developments/Strategic Initiatives
10.4.2. F. Hoffman-La Roche Ltd.
10.4.2.1. Participant’s Overview
10.4.2.2. Financial Performance
10.4.2.3. Product Benchmarking
10.4.2.4. Recent Developments/Strategic Initiatives
10.4.3. QIAGEN
10.4.3.1. Participant’s Overview
10.4.3.2. Financial Performance
10.4.3.3. Product Benchmarking
10.4.3.4. Recent Developments/Strategic Initiatives
10.4.4. Thermo Fisher Scientific, Inc.
10.4.4.1. Participant’s Overview
10.4.4.2. Financial Performance
10.4.4.3. Product Benchmarking
10.4.4.4. Recent Developments/Strategic Initiatives
10.4.5. Bio-Rad Laboratories, Inc.
10.4.5.1. Participant’s Overview
10.4.5.2. Financial Performance
10.4.5.3. Product Benchmarking
10.4.5.4. Recent Developments/ Strategic Initiatives
10.4.6. Oxford Nanopore Technologies
10.4.6.1. Participant’s Overview
10.4.6.2. Financial Performance
10.4.6.3. Product Benchmarking
10.4.6.4. Recent Developments/Strategic Initiatives
10.4.7. PierianDx
10.4.7.1. Participant’s Overview
10.4.7.2. Financial Performance
10.4.7.3. Product Benchmarking
10.4.7.4. Recent Developments/Strategic Initiatives
10.4.8. Genomatix GmbH
10.4.8.1. Participant’s Overview
10.4.8.2. Financial Performance
10.4.8.3. Product Benchmarking
10.4.8.4. Recent Developments/Strategic Initiatives
10.4.9. DNASTAR, Inc.
10.4.9.1. Participant’s Overview
10.4.9.2. Financial Performance
10.4.9.3. Product Benchmarking
10.4.9.4. Recent Developments/Strategic Initiatives
10.4.10. Perkin Elmer, Inc.
10.4.10.1. Participant’s Overview
10.4.10.2. Financial Performance
10.4.10.3. Product Benchmarking
10.4.10.4. Recent Developments/Strategic Initiatives